WebPortfolio Name: Pulmokine. Pulmokine is a biopharmaceutical company developing a novel class of kinase inhibitors for pulmonary related diseases. Its first program, currently in clinical development, is an inhaled small molecule inhibitor of PDGFR for the treatment of pulmonary arterial hypertension (PAH). WebDESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a rare disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel combined JAK1/JAK2 inhibitor or more selective JAK2 inhibitor for PAH that will be delivered by inhalation.

Alzheon Pipeline Preserving Future Memories

WebContact Email [email protected]. Phone Number (518) 472-0952. Pulmokine is a privately held biopharmaceutical company. Our focus is on pulmonary disease and … WebOct 31, 2024 · It was licensed from Pulmokine, Inc. in 2024. Gossamer paid $5.5 million upfront and has made a $5 million payment for entering the Phase 2 trial. djay 2 music library

Pulmokine Receives $1 Million Investment from Broadview

WebDebra is a d, s at Pulmokine, Inc. Renting a two bedroom apartment in the zip code 12159 may cost you $1,320 per month, PD&R says. The popularity rank for the name Debra was 2943 in the US in 2024, the Social Security Administration's data shows . … Webabout us. Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. WebJun 15, 2024 · Seralutinib reduced the mean pulmonary arterial pressure more than imatinib, by 37% versus 27%. It also lowered right ventricle pressure by 45% versus 28%. These differences, however, were not statistically significant. Compared with imatinib, seralutinib had a significantly greater effect on measures of heart function. crawfish etouffee rose